To include your compound in the COVID-19 Resource Center, submit it here.

Argos falls on Phase IIb miss in HIV

Argos Therapeutics Inc. (NASDAQ:ARGS) plunged $3.10 (32%) to $6.51 on Friday after reporting that AGS-004 missed the primary endpoint of a 1.1 log reduction in median viral load after 12 weeks of

Read the full 323 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE